QQQ   295.61 (-3.45%)
AAPL   142.92 (-4.23%)
MSFT   257.02 (-3.67%)
FB   196.03 (-3.25%)
GOOGL   2,263.09 (-2.85%)
AMZN   2,179.73 (-5.53%)
TSLA   729.31 (-4.24%)
NVDA   173.40 (-4.60%)
BABA   89.10 (-3.14%)
NIO   16.13 (-3.01%)
AMD   98.51 (-3.86%)
CGC   5.74 (-2.55%)
MU   71.75 (-3.67%)
T   20.44 (-0.63%)
GE   75.52 (-1.15%)
F   12.96 (-4.21%)
DIS   105.57 (-2.83%)
AMC   13.39 (+3.80%)
PFE   50.42 (-1.79%)
PYPL   78.13 (-2.03%)
NFLX   182.51 (-4.22%)
QQQ   295.61 (-3.45%)
AAPL   142.92 (-4.23%)
MSFT   257.02 (-3.67%)
FB   196.03 (-3.25%)
GOOGL   2,263.09 (-2.85%)
AMZN   2,179.73 (-5.53%)
TSLA   729.31 (-4.24%)
NVDA   173.40 (-4.60%)
BABA   89.10 (-3.14%)
NIO   16.13 (-3.01%)
AMD   98.51 (-3.86%)
CGC   5.74 (-2.55%)
MU   71.75 (-3.67%)
T   20.44 (-0.63%)
GE   75.52 (-1.15%)
F   12.96 (-4.21%)
DIS   105.57 (-2.83%)
AMC   13.39 (+3.80%)
PFE   50.42 (-1.79%)
PYPL   78.13 (-2.03%)
NFLX   182.51 (-4.22%)
QQQ   295.61 (-3.45%)
AAPL   142.92 (-4.23%)
MSFT   257.02 (-3.67%)
FB   196.03 (-3.25%)
GOOGL   2,263.09 (-2.85%)
AMZN   2,179.73 (-5.53%)
TSLA   729.31 (-4.24%)
NVDA   173.40 (-4.60%)
BABA   89.10 (-3.14%)
NIO   16.13 (-3.01%)
AMD   98.51 (-3.86%)
CGC   5.74 (-2.55%)
MU   71.75 (-3.67%)
T   20.44 (-0.63%)
GE   75.52 (-1.15%)
F   12.96 (-4.21%)
DIS   105.57 (-2.83%)
AMC   13.39 (+3.80%)
PFE   50.42 (-1.79%)
PYPL   78.13 (-2.03%)
NFLX   182.51 (-4.22%)
QQQ   295.61 (-3.45%)
AAPL   142.92 (-4.23%)
MSFT   257.02 (-3.67%)
FB   196.03 (-3.25%)
GOOGL   2,263.09 (-2.85%)
AMZN   2,179.73 (-5.53%)
TSLA   729.31 (-4.24%)
NVDA   173.40 (-4.60%)
BABA   89.10 (-3.14%)
NIO   16.13 (-3.01%)
AMD   98.51 (-3.86%)
CGC   5.74 (-2.55%)
MU   71.75 (-3.67%)
T   20.44 (-0.63%)
GE   75.52 (-1.15%)
F   12.96 (-4.21%)
DIS   105.57 (-2.83%)
AMC   13.39 (+3.80%)
PFE   50.42 (-1.79%)
PYPL   78.13 (-2.03%)
NFLX   182.51 (-4.22%)
NASDAQ:NLTX

Neoleukin Therapeutics News Headlines

$1.10
-0.01 (-0.90%)
(As of 05/18/2022 11:58 AM ET)
Add
Compare
Today's Range
$1.06
$1.14
50-Day Range
$0.98
$2.36
52-Week Range
$0.92
$11.34
Volume
3,056 shs
Average Volume
307,713 shs
Market Capitalization
$46.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.25
Get Neoleukin Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NLTX and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

Neoleukin Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

NLTX
News Sentiment

0.41

0.33

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

NLTX Articles
This Week

3

0

NLTX Articles
Average Week



Neoleukin Therapeutics (NASDAQ:NLTX) News Headlines Today

SourceHeadline
MarketBeat logoShort Interest in Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) Expands By 22.6%
americanbankingnews.com - May 18 at 2:04 AM
MarketBeat logoNeoleukin Therapeutics (NASDAQ:NLTX) Downgraded by Zacks Investment Research to Hold
americanbankingnews.com - May 17 at 5:20 AM
finance.yahoo.com logoNeoleukin Therapeutics Announces First Patient Treated in Combination Arm of Phase 1 Trial Evaluating NL-201 in Combination with KEYTRUDA® (pembrolizumab)
finance.yahoo.com - May 16 at 9:04 AM
seekingalpha.com logoNeoleukin Therapeutics GAAP EPS of -$0.28 beats by $0.02
seekingalpha.com - May 9 at 8:34 PM
finance.yahoo.com logoNeoleukin Therapeutics Announces First Quarter 2022 Financial Results and Corporate Update
finance.yahoo.com - May 9 at 8:34 PM
MarketBeat logoZacks Investment Research Upgrades Neoleukin Therapeutics (NASDAQ:NLTX) to Buy
americanbankingnews.com - May 6 at 4:28 AM
seekingalpha.com logoNeoleukin announces preclinical data for immunotherapy candidate NL-201, shares fall
seekingalpha.com - April 13 at 1:51 PM
finance.yahoo.com logoNeoleukin Therapeutics Announces Preclinical Data for NL-201 at American Association for Cancer Research (AACR) Annual Meeting
finance.yahoo.com - April 13 at 1:51 PM
finance.yahoo.com logoNeoleukin Therapeutics to Present at Canaccord Genuity Horizons in Oncology Conference
finance.yahoo.com - April 7 at 8:28 AM
finance.yahoo.com logoNeoleukin Therapeutics Announces Appointment of Donna Cochener as General Counsel
finance.yahoo.com - March 15 at 10:27 AM
finance.yahoo.com logoNeoleukin Therapeutics Announces Multiple Presentations at American Association for Cancer Research (AACR) Annual Meeting
finance.yahoo.com - March 8 at 6:54 PM
benzinga.com logoRecap: Neoleukin Therapeutics Q4 Earnings
benzinga.com - March 1 at 10:56 PM
finance.yahoo.com logoNeoleukin Therapeutics Announces Year End 2021 Financial Results and Corporate Update
finance.yahoo.com - March 1 at 5:38 PM
finance.yahoo.com logoNeoleukin Therapeutics to Present at Guggenheim Healthcare Talks 2022 Oncology Conference
finance.yahoo.com - February 3 at 8:39 AM
nasdaq.com logoAs Neoleukin Therapeutics, Inc.'s market cap (NASDAQ:NLTX) drops to US$138m, insiders might be questioning their decision to buy earlier this year
nasdaq.com - January 24 at 3:20 PM
finance.yahoo.com logoAs Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) drops to US$138m market cap, insiders might rethink their US$1.4m stock purchase earlier this year
finance.yahoo.com - January 24 at 3:20 PM
nasdaq.com logoNeoleukin Therapeutics, Inc. Common Stock (NLTX)
nasdaq.com - January 20 at 7:45 PM
nasdaq.com logoNeoleukin Therapeutics Inc Shares Fall 0.8% Below Previous 52-Week Low - Market Mover
nasdaq.com - January 14 at 3:04 AM
nasdaq.com logoNeoleukin Therapeutics Inc Shares Fall 2.1% Below Previous 52-Week Low - Market Mover
nasdaq.com - January 13 at 2:00 AM
seekingalpha.com logoMerck says Keytruda met main goal in a first-of-its-kind trial for lung cancer
seekingalpha.com - January 10 at 8:08 PM
benzinga.com logoNeoleukin Therapeutics Announces Clinical Collaboration With Merck To Evaluate NL-201 In Combination With KEYTRUDA
benzinga.com - January 10 at 10:08 AM
seekingalpha.com logoMerck in pact with Neoleukin to study Keytruda combo in cancer trial
seekingalpha.com - January 10 at 10:08 AM
finance.yahoo.com logoNeoleukin Therapeutics Announces Clinical Collaboration with Merck to Evaluate NL-201 in Combination with KEYTRUDA® (pembrolizumab)
finance.yahoo.com - January 10 at 10:08 AM
nasdaq.com logoNeoleukin Therapeutics Inc Shares Fall 3.3% Below Previous 52-Week Low - Market Mover
nasdaq.com - January 8 at 1:19 AM
nasdaq.com logoNeoleukin Therapeutics Inc Shares Close the Day 10.4% Higher - Daily Wrap
nasdaq.com - December 23 at 12:22 AM
benzinga.com logoNeoleukin Therapeutics Announces Preclinical Data...
benzinga.com - December 12 at 12:03 AM
finance.yahoo.com logoNeoleukin Therapeutics Announces Preclinical Data Highlighting Activity of NL-201 in Hematologic Malignancies at 63rd American Society of Hematology Annual Meeting (ASH 2021)
finance.yahoo.com - December 11 at 6:49 PM
finance.yahoo.com logoNeoleukin Therapeutics Presents NL-201 Preclinical Data at Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021)
finance.yahoo.com - November 12 at 12:07 PM
finance.yahoo.com logoNeoleukin Therapeutics to Present at Upcoming Investor Conferences
finance.yahoo.com - November 9 at 9:39 AM
finance.yahoo.com logoNeoleukin Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Update
finance.yahoo.com - November 4 at 6:40 PM
finance.yahoo.com logoHere's What Neoleukin Therapeutics, Inc.'s (NASDAQ:NLTX) Shareholder Ownership Structure Looks Like
finance.yahoo.com - October 25 at 3:40 PM
ca.finance.yahoo.com logoNeoleukin Therapeutics, Inc. (NLTX)
ca.finance.yahoo.com - October 15 at 12:36 AM
finance.yahoo.com logoNeoleukin Therapeutics Announces Multiple Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021)
finance.yahoo.com - October 1 at 12:36 PM
finance.yahoo.com logoNeoleukin Therapeutics Announces Oral Presentation at IDWeek 2021 of Data Demonstrating that NL-CVX1, a Computationally Designed De Novo Protein, Can Block Infection by SARS-CoV-2 Viral Variants of Concern
finance.yahoo.com - September 29 at 8:12 PM
finance.yahoo.com logoNeoleukin Therapeutics Announces Appointment of Bill Arthur, Ph.D., as Vice President and Head of Research
finance.yahoo.com - September 9 at 9:01 AM
nasdaq.com logoFriday 8/27 Insider Buying Report: NLTX, CYXT
nasdaq.com - August 27 at 4:38 PM
finance.yahoo.com logoNeoleukin Therapeutics Announces Second Quarter 2021 Financial Results & Provides Corporate Update
finance.yahoo.com - August 5 at 7:24 PM
msn.com logoMDNA: CTA Submitted in Australia; Phase 1 Trial of MDNA11 to Initiate 3Q21…
msn.com - June 28 at 12:33 PM
finance.yahoo.com logoInsider Buying: The Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) CEO, President & Director Just Bought 2.3% More Shares
finance.yahoo.com - June 8 at 7:35 AM
finance.yahoo.com logoNeoleukin Therapeutics to Participate in Jefferies Virtual Healthcare Conference
finance.yahoo.com - May 26 at 1:06 PM
finance.yahoo.com logoIs Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) Popular Amongst Insiders?
finance.yahoo.com - May 17 at 7:16 PM
msn.com logoBRIEF-Neoleukin Therapeutics Says Entered Clinical Development With First Patient Dosed In Phase 1 Trial Of Nl-201
msn.com - May 12 at 6:01 PM
finance.yahoo.com logoNeoleukin Therapeutics Announces Initiation of Phase 1 NL-201 Trial
finance.yahoo.com - May 5 at 8:37 AM
finance.yahoo.com logoNeoleukin Therapeutics to Participate in BofA Securities 2021 Healthcare Conference
finance.yahoo.com - May 4 at 12:11 PM
finance.yahoo.com logoNeoleukin Therapeutics Announces Appointment of Priti Patel, M.D., M.S., as Chief Medical Officer
finance.yahoo.com - May 3 at 12:55 PM
nasdaq.com logoDo Insiders Own Lots Of Shares In Neoleukin Therapeutics, Inc. (NASDAQ:NLTX)?
nasdaq.com - April 29 at 1:09 PM
seekingalpha.com logoNeoleukin Therapeutics, Inc.'s (NLTX) CEO Jonathan Drachman on Q4 2020 Results - Earnings Call Transcript
seekingalpha.com - March 27 at 3:45 AM
finance.yahoo.com logoNeoleukin Therapeutics Announces Year End 2020 Financial Results
finance.yahoo.com - March 25 at 8:47 PM
finance.yahoo.com logoNeoleukin Therapeutics to Host 2020 Financial Results Conference Call and Webcast on March 25, 2021
finance.yahoo.com - March 18 at 12:11 PM
finance.yahoo.com logoNeoleukin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - March 2 at 10:44 AM
Get Neoleukin Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NLTX and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 5/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.